Julien Van Damme
@vandamme_jvd
Join us this morning for the graduation of the French speaking urologists in @sb_uro #Belgium @Maggie_DeBlock @ThRoumeguere @ULBruxelles @DrFrancoisHerve @vandamme_jvd @ClinUnivStLuc @chr_assenmacher @UniversiteLiege @AFSpinoit online graduation!
Manon Dewandre présente son évaluation urodynamique des bandelettes sous-urethrales trans-obturatrices dans l'incontinence d'effort après prostactectomie. @sb_uro @ThRoumeguere @DrFrancoisHerve @vandamme_jvd @AFSpinoit @ClinUnivStLuc @UniversiteLiege @ULBruxelles
Had the pleasure of presenting a poster of EORTC 2418 STARBURST-1 at #anzup25. It’s time to validate a clinical multimodal signature of response to neoadjuvant treatment in MIBC! @amassonlecomte @Achard_Verane @GGrisay @y_loriot @BertrandTOMBAL @EORTC @ANZUPtrials
🌟Challenges in Defining Clinical CR to Systemic Therapy in MIBC🌟 @EORTC #STARBURST project 🖋️ Alexandra Masson-Lecomte @AFUrology, Guillaume Grisay, @vandamme_jvd, @Achard_Verane , @LAUrology_NL, @robert_huddart, @frasor86, @LDyrskjot, Yves Allory @institut_curie,…
✨ JUST OUT in EUO, New paper challenging a dogma. ⏩ MUST READ: @ConstanceHuck has done a great job to show that CIS is not always a contra-indication for Trimodal Therapy in the management of MIBC. 🙏Thanks to all co-authors for their input! sciencedirect.com/science/articl…
Why attend #RENALC25, #BLADDR25 and #PROSCA25? Hear it straight from @Achard_Verane in this quick video 👇 ➡️ Register now: tinyurl.com/mryx8kwe 💎Dive into the clinical application of new GU oncology data 👥 Learn from multidisciplinary experts 🗓️3-6 December 2025 | 📍…
How exciting to see all these new data at #ASCO25! 👀 Interested to hear how these data are translated to your clinical practice? 👂 At the Global Forum on GU Oncology, the impact of the latest findings on #RenalCancer, #BladderCancer and #ProstateCancer are discussed in a…
Well done! The @ANZUPTrials #BCGMM trial has been presented @ASCO25 showing BCG plus mitomycin a safe & effective alternative to BCG alone & the added benefit of requiring 40% fewer BCG doses. Congrats to Prof Dickon Hayne & team @Prof_IanD @TrialsCentre @MSD_Aus #OmegaPharm
@ANZUPtrials rand PhIII ANZUP 1301 of intravesical MMC + BCG vs BCG in tx-naive #HR-NMIBC ➡️ no sig diff in DFS, time to recurrence or progression, or OS between arms. Post-hoc suggests MMC addition may benefit in higher-risk (all T1, CIS) subgroup #ASCO25 @OncoAlert
🚨 Defining clinical response to neoadjuvant CT in bladder is crucial to offer bladder-sparing strategies in complete or near cplt responders ! EORTC Starbust-1 will launch soon @amassonlecomte @EORTC @y_loriot @BertrandTOMBAL @Achard_Verane @vandamme_jvd sciencedirect.com/science/articl…
Fast (< 30 min) “All-in-One” whole-body MRI for TNM staging in high-risk prostate cancer (PCa), clearly an alternative @ClinUnivStLuc @irec_ -IX ejradiology.com/article/S0720-…
Merci aux intervenants @MRoupret @PignotG @evanguelosx @RoubaudG @WesKassouf @aleberlin2 @GenevieveLOOS12 @PaulSargos ➡️ Vidéo dédiée aux patients @CancerVessie @BladderCancerUS @BladderCancerCA @BCCWalkMontreal @WorldBladderCan @BladderCancerUK
🚀Congratulations to Dr @GGrisay & Dr @vandamme_jvd for presenting the groundbreaking EORTC-2418-GUCG STARBURST-1 study last week at #ASCOGU in San Francisco! This study aims to redefine treatment for muscle-invasive #BladderCancer. 👉urotoday.com/conference-hig… @ASCO
Had the pleasure of presenting a poster of EORTC2418 - STARBURST1 at #GU25 ! It's vital to validate a clinical multimodal signature of response to NAT in MIBC ! Alexandra Masson-Lecomte @Achard_Verane @vandamme_jvd @BertrandTOMBAL @y_loriot @EORTC
Great to see #EORTC2418 - STARBURST1 being presented at #GU25! Validating a clinical multimodal signature of response to NAT in MIBC is a crucial step towards more personalized treatment strategies. Honored to be part of this important study alongside such a dedicated team!
Had the pleasure of presenting a poster of EORTC2418 - STARBURST1 at #GU25 ! It's vital to validate a clinical multimodal signature of response to NAT in MIBC ! Alexandra Masson-Lecomte @Achard_Verane @vandamme_jvd @BertrandTOMBAL @y_loriot @EORTC
We have performed a review dedicated to this topic... Just submitted. 🙏 With @ConstanceHuck @Achard_Verane @evanguelosx @MRoupret @BertrandTOMBAL @drjefstathiou @vandammeju @achoud72 ✨Trial to come... 🤞 @Achard_Verane
Check out our free 20-minute webinar with a multidisciplinary panel of experts discussing the most recent data from clinical trials, treatment (de)escalation, and the role of ultra-low PSA in #mHSPC Register for free at library.mirrorsmed.org/?utm_code=SoMe… @vandamme_jvd @OncoAlert #GU…
Nice talk by Dr Masson-Lecomte on the importance of defining the response to NAT, as well as the importance of multimodal assessment. Question will be answered by the EORTC2418 - ‘STARBURST’ study !#EORTC #EMUC24 @y_loriot @Achard_Verane @vandamme_jvd @GGrisay @BertrandTOMBAL
Congrats to @vandamme_jvd @GIZZIMarcoMd for this nice poster #EMUC24 @BertrandTOMBAL
There is more than PET-PSMA to monitor tumor response in advance PCa. @vandamme_jvd @VPasoglou @FLecouvet @ProfPadhani sciencedirect.com/science/articl…
Fertility preservation in #TesticularCancer patients. Presentation by @vandamme_jvd. #ESOU21 written coverage by @zklaassen_md @GACancerCenter on UroToday > bit.ly/36ojabX @Uroweb @UrowebESU @EAU_Uroonco
Serving a « Grappa » like in Rome 🥃🤫
I was lured in to the #bau20 as they said I would enjoy a “great view on Bxl airport....” It was a pleasure and an honor but I am afraid they have never seen Rome! Luckily we had @vandamme_jvd “the butler”! :) @EveraertsW @sb_uro @PietDirix @MaartenAlbersen